QATCH Technologies

QATCH Technologies develops microfluidic instrumentation and sensor technology designed to de-risk the preclinical phase of biopharmaceutical drug development. The company’s core technology, marketed under the nanovisQ brand, utilizes microfluidic capillary viscometers on quartz resonators to characterize the viscosity and injectability of high-concentration protein formulations. This approach allows researchers to perform measurements across a wide range of shear rates using very small sample volumes—typically only 3 to 5 microliters—and obtain results within minutes, addressing challenges related to manufacturing and formulation stability at early stages of discovery.

The technology enables pharmaceutical developers to screen formulations earlier in the process, reducing the material requirements often associated with traditional testing methods. By providing precise data on how formulations behave under various shear conditions, QATCH helps teams make informed decisions regarding lead selection and manufacturability, ultimately aiming to prevent delays in delivering medicines. Based in Durham, North Carolina, and founded in 2016, the company has received multiple SBIR and STTR grants from organizations including the NIH, NIST, and NSF to support the development and commercialization of its testing platforms and services.